• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific launches U.S. Parkinson’s trial, cites interim EU data

Boston Scientific launches U.S. Parkinson’s trial, cites interim EU data

June 18, 2013 By Brad Perriello

Boston Scientific launches U.S. Parkinson's trial, cites interim EU data

Boston Scientific (NYSE:BSX) said it launched a U.S. clinical trial of its Vercise deep-brain stimulation treatment for patients with Parkinson’s disease and touted interim results from a European study of the device.

The Natick, Mass.-based medical device company said the Intrepid trial is designed to evaluate the safety and efficacy of the device in improving motor function and quality of life for patients with the neurological condition. The 1st patient in the trial received the device at Cedars-Sinai hospital in Los Angeles.

The Vercise device has CE Mark approval in the European Union and won a nod from Australia’s Therapeutic Goods Administration, according to a press release. BSX touts the device as the only DBS system with adjustable current flow to allow doctors to manipulate the current in "fine increments," according to the release.

In a separate statement, Boston Scientific said interim results from a European trial of the Vercise device showed "a significant improvement in motor scores" in data presented at the International Congress of Parkinson’s Disease & Movement Disorders in Sydney.

Preliminary analysis of data from the 40-patient Vantage study showed a roughly 60% mean improvement in motor function after 6 months, according to a press release.

"The Vantage study is a key facet of our DBS program and emphasizes our commitment to advancing therapy through clinical research with the Vercise DBS System," Maulik Nanavaty, Boston Scientific neuromodulation president, said in prepared remarks.  "The significance of the reduction in motor scores is a testament to the capabilities of the Vercise System.  We continuously strive to develop innovative technologies that improve patient outcomes."

Filed Under: News Well Tagged With: Boston Scientific, Clinical Trials, Deep-brain stimulation, Parkinson's disease

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy